CN106716136B - 多囊性肾病的生物标志物及其用途 - Google Patents

多囊性肾病的生物标志物及其用途 Download PDF

Info

Publication number
CN106716136B
CN106716136B CN201580053081.4A CN201580053081A CN106716136B CN 106716136 B CN106716136 B CN 106716136B CN 201580053081 A CN201580053081 A CN 201580053081A CN 106716136 B CN106716136 B CN 106716136B
Authority
CN
China
Prior art keywords
pkd
cyclin
levels
leu
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580053081.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106716136A (zh
Inventor
O·别斯克罗夫内亚
N·布卡诺夫
S·莫雷诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CN106716136A publication Critical patent/CN106716136A/zh
Application granted granted Critical
Publication of CN106716136B publication Critical patent/CN106716136B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN201580053081.4A 2014-08-04 2015-08-03 多囊性肾病的生物标志物及其用途 Active CN106716136B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033031P 2014-08-04 2014-08-04
US62/033,031 2014-08-04
PCT/US2015/043497 WO2016022500A2 (en) 2014-08-04 2015-08-03 Biomarkers of polycystic kidney disease and uses thereof

Publications (2)

Publication Number Publication Date
CN106716136A CN106716136A (zh) 2017-05-24
CN106716136B true CN106716136B (zh) 2020-06-23

Family

ID=54035292

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580053081.4A Active CN106716136B (zh) 2014-08-04 2015-08-03 多囊性肾病的生物标志物及其用途

Country Status (12)

Country Link
US (1) US10871495B2 (enExample)
EP (1) EP3177932B1 (enExample)
JP (2) JP6730252B2 (enExample)
KR (1) KR20170033436A (enExample)
CN (1) CN106716136B (enExample)
AU (1) AU2015301278A1 (enExample)
BR (1) BR112017002003A2 (enExample)
CO (1) CO2017001596A2 (enExample)
MX (1) MX2017001648A (enExample)
RU (1) RU2017106891A (enExample)
SG (1) SG11201700290SA (enExample)
WO (1) WO2016022500A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116755B2 (en) 2015-11-18 2021-09-14 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
GB201719520D0 (en) * 2017-11-24 2018-01-10 Univ College Cardiff Consultants Ltd Neuroprotectvie peptide
KR102859441B1 (ko) * 2019-11-22 2025-09-12 서울대학교산학협력단 Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003500418A (ja) * 1999-05-24 2003-01-07 エイブイアイ バイオファーマ， インコーポレイテッド 多発性嚢胞腎疾患の処置のためのｃ−ｍｙｃに対するアンチセンス
US9006181B2 (en) 2004-07-21 2015-04-14 The Administrators Of The Tulane Educational Fund Treatment of renal dysfunction and multiple myeloma using PACAP compounds
EP1808694A1 (en) 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
US20120077263A1 (en) 2009-06-05 2012-03-29 Mayo Foundation For Medical Education And Research Methods and materials for isolating exosomes
CN102018702B (zh) * 2009-09-16 2012-07-18 北京大学 银杏内酯b的一种用途
US20140079769A1 (en) * 2010-10-01 2014-03-20 Fabiola Terzi Methods for predicting the progression and treating a chronic kidney disease in a patient
US20130276513A1 (en) * 2010-10-14 2013-10-24 The Regents Of The University Of California Methods for diagnosing and assessing kidney disease
ES2982997T3 (es) 2012-07-03 2024-10-21 Fond Centro San Raffaele 2-desoxiglucosa para uso en el tratamiento de la enfermedad renal poliquística dominante autosomal o enfermedad hepática poliquística
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد

Also Published As

Publication number Publication date
EP3177932A2 (en) 2017-06-14
JP2020170013A (ja) 2020-10-15
RU2017106891A3 (enExample) 2019-03-14
RU2017106891A (ru) 2018-09-06
EP3177932B1 (en) 2021-07-14
JP6730252B2 (ja) 2020-07-29
JP7005695B2 (ja) 2022-02-04
CN106716136A (zh) 2017-05-24
BR112017002003A2 (pt) 2017-12-12
KR20170033436A (ko) 2017-03-24
US20170227551A1 (en) 2017-08-10
MX2017001648A (es) 2017-04-27
US10871495B2 (en) 2020-12-22
CO2017001596A2 (es) 2017-05-19
WO2016022500A3 (en) 2016-04-07
SG11201700290SA (en) 2017-02-27
WO2016022500A2 (en) 2016-02-11
JP2017525955A (ja) 2017-09-07
AU2015301278A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
US12150938B2 (en) Biomarker of polycystic kidney disease and uses thereof
Tian et al. Kidney injury molecule-1 is elevated in nephropathy and mediates macrophage activation via the Mapk signalling pathway
JP7005695B2 (ja) 多発性嚢胞腎のバイオマーカーおよびその使用
Bartosik‐Psujek et al. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone
Menkhorst et al. Galectin-7 impairs placentation and causes preeclampsia features in mice
Weng et al. Fiber scaffold bioartificial liver therapy relieves acute liver failure and extrahepatic organ injury in pigs
García-Marchena et al. Psychiatric comorbidity and plasma levels of 2-acyl-glycerols in outpatient treatment alcohol users. Analysis of gender differences
EP3093022B1 (en) Gata-3 inhibitors for use in the treatment of th2-driven asthma
Guo et al. NKRF in Cardiac Fibroblasts Protects against Cardiac Remodeling Post‐Myocardial Infarction via Human Antigen R
Han et al. CXCR4-targeted PET imaging in rheumatoid arthritis: a novel approach for monitoring disease activity and therapeutic response
JP2019502902A5 (enExample)
ES2352045T3 (es) Diferenciación entre las meningitis bacterianas y víricas.
JP2017525955A5 (enExample)
Yin et al. MMP‐7 affects peritoneal ultrafiltration associated with elevated aquaporin‐1 expression via MAPK/ERK pathway in peritoneal mesothelial cells
Liu et al. Gadopentetate meglumine activates mast cells to cause IgE-independent allergic reactions both in vitro and in vivo
Guo et al. Erythrocytosis caused by giant chromophobe renal cell carcinoma: a case report indicating a 9-year misdiagnosis of polycythemia vera
AU2020381573A1 (en) Methods and compositions for determining OXPL-associated diseases and disorders
Douglass Hippocampal Insulin Exists! In Vivo Sampling Methods, Basal Concentrations, Recurrent Hypoglycemia, And Behavioral Extracellular Insulin Responses
Ma et al. Adenosine monophosphate, one metabolite from lower respiratory tract, promotes the progression of pulmonary arterial hypertension through the PI3K/AKT signaling pathway in pediatric with congenital heart disease
Majid et al. Diagnostic potential of serum biomarkers including HMGB1 and Klotho in cognitive impairment among type 2 diabetes mellitus patients: a case–control study
JP2018205158A (ja) α１−アンチキモトリプシンを含むバイオマーカー
Ahmed Meprin B Activity Modulates Downstream Mediators of the Protein Kinase A Signaling Pathway in Ischemia/Reperfusion Induced Acute Kidney Injury

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant